Rubal BediVenture Partner and Head of Corporate Venture Group at HOYA
Rubal Bedi is the Global Head and Vice-President of Corporate Venture Capital at HOYA Corporation, a $40 billion multinational company, focusing on medical device, diagnostic, and digital health investments. Currently, Rubal represents HOYA on the boards of Centricity, Cryosa, Lensgen, and Novuson. Before joining HOYA, Rubal was at Ascension Ventures, a hospital-based venture capital fund, where he led investments in BardyDx and Neuronetics (IPO). Rubal previously worked at Medtronic, where he led business development and strategy within the Aortic and Peripheral Vascular division, a $1.6 billion business unit. While he was at Medtronic, Rubal led investments in Shockwave Medical (IPO) and Arsenal Medical and served on the boards of TVA Medical (acquired) and 480 Biomedical/Lyra Therapeutics (IPO). Prior to his tenure at Medtronic, Rubal worked at PTV Healthcare Capital, a late-stage venture and growth equity firm. During his time there, Rubal worked with the entrepreneur in residence in the formation of Apollo Endosurgery (IPO). He received an MBA from the McCombs School of Business at the University of Texas at Austin and a BA in Economics from the University of California at Irvine. Outside of Ascension Ventures, he enjoys spending time with his family, rooting for his Bay Area sports teams, and traveling internationally.